Intravenous busulfan (IV BU) has demonstrated safety when administered at 0.8 mg/kg per dose IV every 6 hours ϫ 16 doses. We evaluated the safety and pharmacokinetics (PK) of giving the same total daily IV BU dose (3.2 mg/kg) either divided as a twice-daily infusion or as a single infusion to patients undergoing hematopoietic stem cell transplantation (HSCT). Twelve patients with hematologic malignant disease were treated; 7 patients had non-Hodgkin's lymphoma, 4 patients had acute myeloid leukemia, and 1 patient had chronic myelogenous leukemia. The first cohort (group A) received, on the basis of actual body weight, IV BU at 1.6 mg/kg per dose over 4 hours every 12 hours for 4 days (day -7 to day -4). The second cohort (group B) received 3.2 mg/kg per dose of IV BU (same total dose as group A) as a single infusion over 4 hours daily for 4 days. In both groups the IV BU was followed by cyclophosphamide 60 mg/kg daily for 2 days (day -3 and day -2). Blood specimens were collected on the first, fifth, and seventh doses for group A and on the first and fourth doses for group B to determine the disposition of IV BU. Peripheral blood stem cells (autologous in 7 cases and HLA-matched allogeneic in 5 cases) were given 2 days after completion of cyclophosphamide administration (day 0), and granulocyte colony-stimulating factor 5 µg/kg was started on the same day. GVHD prophylaxis consisted of tacrolimus plus methotrexate for recipients of allogeneic stem cells. One patient developed presumed fungal pneumonia and died of multisystem organ dysfunction on day +21 before hematologic reconstitution could be evaluated. Another was reported to have sudden death of undetermined cause at home on day 40. The remaining patients had engraftment (absolute neutrophil count >500/µL) at a median of 11 days and sustained platelet counts >20,000/µL at a median of 14 days. Significant regimen-related toxicity (grade III-IV) was limited to hepatic toxicity (2 cases) catheter infection (2 cases), epistaxis (3 cases), diarrhea (1 case), anorexia (1 case), mucositis (1 case), hyperglycemia (1 case), pneumonia (1 case), and sepsis (1) . In group B there was 1 case of mild venoocclusive disease, which resolved without sequelae. No central nervous system or pulmonary toxicity was noted. Pharmacokinetic parameters, including clearance, half-life, maximum concentration, and area under the curve, demonstrated that the first dose profile was highly predictive of later dose PK profiles. No accumulation of the drug was noted. The change in dosing schedule did not increase toxicity or end-organ damage despite higher plasma concentration-times. Although further study for long-term efficacy is warranted, IV BU can be given safely with reproducible results on a twice-daily divided or single-daily dosing schedule to patients undergoing HSCT.
INTRODUCTION
Busulfan [1,4- bis-(methanesulfonyloxy)butane] is a bifunctional alkylating agent first described by Haddow and Timmis [1] . It was initially introduced as palliative therapy for chronic myeloid leukemia and has been available in the United States as a 2-mg tablet. The potent antitumor effects of the drug led Santos and Tutschka to investigate the use of busulfan to create a murine model of aplastic anemia [2] .
This model system was used to introduce high-dose oral busulfan-based combination chemotherapy for pretransplantation conditioning, most commonly in combination with cyclophosphamide (BU/CY2). The combination has proved to be an integral and effective component of conditioning regimens used in the treatment of patients with hematologic and nonhematologic malignant diseases who are undergoing allogeneic or autologous hematopoietic stem cell transplantation (HSCT) [3] [4] [5] [6] [7] [8] [9] . The standard oral BU/CY2 regimen includes administration of busulfan at a dose and schedule of 1.0 mg/kg every 6 hours for a total of 16 doses.
Although busulfan is effective when used in this regimen, the therapeutic potential of the drug has been compromised owing to inherent problems associated with oral administration. Most notable are variable bioavailability and unpredictable systemic exposure over the course of treatment, primarily because of erratic absorption [10, 11] . Pharmacokinetic (PK) monitoring of busulfan has been used in an effort to address this variability; however, PK data cannot be obtained for up to 25% of patients because of delayed absorption and/or elimination and for a number of patients who have vomited all or part of the intended drug dose [12] . The erratic levels have contributed to variations in systemic busulfan concentration. The variation in concentration leads to increased risk of toxicity due to overexposure [12, 13] or to increased risk of graft failure and/or leukemic relapse due to suboptimal drug levels [14] .
Andersson et al. [15] , using dimethyl acetamide and polyethylene glycol 400, developed a soluble formulation of busulfan that became commercially available in 1999. This pharmaceutically acceptable formulation allowed for a stable dissolved drug that could be diluted further in either normal saline or 5% dextrose in water and delivered parenterally with 100% bioavailability [15, 16] . The published data from the phase I trial determined the dose of 0.8 mg/kg body weight to yield PK parameters similar to those obtained after a standard oral dose of 1 mg/kg body weight [17] . These PK data were supported in a recently completed phase II trial [18] in which patients with advanced hematologic malignant disease were treated with 16 doses of intravenous (IV) BU at 0.8 mg/kg every 6 hours followed by 2 daily doses of cyclophosphamide at 60 mg/kg IV. The regimen was well tolerated, and the safety and efficacy of the dose and regimen were confirmed. Data from this trial demonstrated a more consistent dosing and PK profile than that reported with use of oral busulfan [12] .
Unlike other alkylating agents, busulfan is not cell-cycle specific. Most alkylating agents are dosed on a daily schedule. In the case of busulfan, because of the availability of only 2-mg tablets, investigators in the initial clinical studies prescribed divided busulfan doses administered every 6 hours to improve patient compliance (P. Tutschka, personal communication, 1999) . Alternate dosing of busulfan has been inves-tigated. Preclinical data are available on once-daily dosing in animal models [19, 20] . In the treatment of children, busulfan has been given orally as a daily dose without increased toxicity [21] . Daily dosing and twice-daily dosing schedules of busulfan have been investigated in the adult population; however, there is a lack of PK data on these schedules.
In this study we evaluated administration of IV BU in a modified IV BU/CY2 regimen in the treatment of patients with hematologic malignant disease undergoing HSCT. The PK and safety profiles associated with these schedules were evaluated, and initial findings are presented.
METHODS

Protocol Eligibility
Written informed consent was obtained from all participants in the study. The protocol was approved by the University of Miami Medical Sciences Committee for the Protection of Human Subjects in Research. The study allowed for enrollment of patients 16 to 65 years of age with advanced hematologic malignant disease who were candidates for HSCT. Five of the 12 patients were at high risk of transplantation-related complications due to persistent or refractory disease. Patient entry criteria included adequate cardiac (left ventricular ejection fraction, >40%), renal (glomerular filtration rate, >50 mL/min), and hepatic function (transaminase levels, <1.5 times normal). Peripheral blood stem cell collection had to contain at least 4 × 10 6 CD34 + cells per kilogram for allogeneic transplantation and more than 1 × 10 6 CD34 + cells per kilogram for autologous transplantation.
Conditioning Regimen
Group A received IV BU (Busulfex, Orphan Medical, Minnetonka, MN) at 1.6 mg/kg every 12 hours for 8 doses from days -7 to day -4. Group B received IV BU 3.2 mg/kg (same total dose) daily for 4 days. The dose of IV BU for both groups was based on actual body weight and was administered in a controlled-rate infusion over 4 hours. The IV BU was followed by cyclophosphamide 60 mg/kg IV over 4 hours daily for 2 days, days -3 and -2, to both groups. All patients were given seizure prophylaxis with phenytoin from day -8 to day -3; doses were adjusted to a therapeutic level of 10-20 µg/mL. After a day of rest, the autologous or allogeneic peripheral blood stem cells were infused on day 0 and followed by granulocyte colonystimulating factor 5 µg/kg IV starting on the same day.
Patients who received allogeneic peripheral blood stem cells received graft-versus-host disease (GVHD) prophylaxis consisting of tacrolimus 0.03 mg/kg daily as a continuous IV infusion and then switched to oral dosing of 0.12 mg/kg per day in divided doses. In addition, methotrexate was given at 10 mg/m 2 on day 1 and at 5 mg/m 2 on days 3, 6, and 11 posttransplantation. Standard support based on our unit policies, including antibiotics and blood transfusion, was provided to the patients in the posttransplantation period.
Pharmacokinetic Sampling and Analysis
In group A, blood samples from a peripheral line were drawn on doses 1 and 7 of the IV BU therapy according to the following schedule: predose and 1.5, 2, 3.5, 4, 4.5, 5.5, 7, 9, 11, and 12 hours from the start of IV BU infusion. Peak and trough levels were measured on dose 5 for quality control. Group B had samples drawn on doses 1 and 4 at the following time points: predose and 1.5, 3, 4, 5, 6, 8, 10, 12, 15, and 18 hours from the start of infusion.
Blood samples were collected in ice-chilled heparinized Vacutainer tubes and plasma separated within 12 hours by centrifugation at 1000g for 10 minutes at 4°C. Plasma samples were stored frozen at -80°C until analysis. The analysis for busulfan was performed with a validated high-performance liquid chromatography assay as described elsewhere [14, 22] . IV BU peak concentration (Cmax) is an observed value. The IV BU area under the plasma concentration versus time curve (AUC) per IV BU dose was calculated by dividing the drug dose by the IV BU plasma clearance (CL) estimate. All PK modeling was performed with ADAPT II software, version 4.0 (BMSR, University of Southern California, Los Angeles, CA) [23] . For group A, the fifth-dose IV BU plasma CL was determined by modeling IV BU plasma concentration versus time data from dose 1 and dose 5. The seventh-dose IV BU plasma CL was determined by modeling all (doses 1, 5, and 7) data. For group B, the fourth-dose IV BU plasma CL was determined by modeling IV BU plasma concentration versus time data from dose 1 and dose 4.
Monitoring
Patients were monitored in 3 different periods. Conditioning was defined as from the start of chemotherapy to the day of transplantation. The early posttransplantation period was day 1 to day 28, and the late posttransplantation period was day 28 to day 100. Patient toxicity was monitored with the National Cancer Institute common grading criteria [24] . The Jones criteria [25] were used for standardized evaluation of venoocclusive disease (VOD). GVHD was graded according to established criteria [26] . Engraftment of neutrophils was defined as an absolute neutrophil count >500/µL for 3 consecutive days. Platelet engraftment was defined as a self-sustained platelet count of 20,000/µL for 3 consecutive days. Relapse was defined as documentation of progressive disease based on reappearance of greater than 5% blasts in the peripheral blood or in the bone marrow (leukemia) or clinical or radiographic growth or progression of lymph nodes (lymphoma or Hodgkin's disease) posttransplantation. Table 1 notes the patient characteristics. The median age of the patients was 52 years (range, 26 to 65 years). Seven patients underwent autologous transplantation: 5 for non-Hodgkin's lymphoma (NHL) and 2 for acute myeloid leukemia (AML). Five patients underwent allogeneic transplantation: 2 for AML, 2 for NHL, and 1 for chronic myelogenous leukemia (CML). Six of the patients were in complete remission (CR) at the time of transplantation, and 2 patients had a partial response (PR) at the time of transplantation. Three patients had relapsed/refractory AML. The patient with CML was in chronic phase.
RESULTS
Patient Characteristics
Busulfan Pharmacokinetics
Results of the PK evaluation are shown in Table 2 . For all the patients the PK data showed minimal intrapatient variation for AUC, half-life (t 1/2 ), CL, or C max of busulfan. Intrapatient variability ranged from less than 1% to 10%.
The median AUC for group A (twice-daily dosing) was 3390 µM*min (range, 2400-4678 µM*min). IV BU infusion gave consistent PK with little change in t 1/2 , CL, or C max on the seventh dose. The fifth dose showed results similar to those with both the first and the seventh dose, although only peak and trough levels were measured. Figure 1 shows a representative PK plot comparison of doses 1 and 7 that demonstrates a very tight profile from dose to dose.
Group B (once-daily dosing) also had similar intrapatient results with small (<10%) variation between doses. Although the C max was higher in this group, the CL of the drug remained the same as that seen with twice-daily dosing. The AUC fell within the expected values for this dose with a median AUC of 5561 µM*min (range, 4414-7368 µM*min). Figure 2 shows a representative PK plot comparison of the AUC for first and fourth doses of a patient in group B. 
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Toxicity Table 3 shows the toxicity profile for the patients during conditioning and to the first 28 days posttransplantation. The majority of toxicity was grade 1 and 2, including nausea, vomiting, diarrhea, fatigue, and insomnia. Grade 3 toxicity included mucositis in 1 patient, anorexia in 1 patient, infection in 2 patients, pneumonia in 1 patient, epistaxis in 2 patients, and hyperglycemia in 1 patient. One patient in group A, who received an allogeneic transplant, developed grade 4 toxicity and died of sepsis, presumed fungal infection, and multiple-system organ failure. One patient in group B was discharged to home after transplantation. On day 40 posttransplantation, he had sudden death of undetermined cause; autopsy was not performed.
Hepatic abnormalities (elevated bilirubin level) were seen in 2 patients. The median total bilirubin level was 1.1 mg/dL (range, 0.7-2.6 mg/dL). One of the patients with hepatic abnormalities developed clinical VOD on day 23 after starting medroxyprogesterone acetate. The process resolved, when the drug was discontinued, by day 43. Transaminase levels, with the exception of the patient who developed VOD, never rose above 3 times normal.
Overall, the toxicity profile was similar to that previously reported in the every-6-hour dosing of IV BU trials [17, 18] . No new or unexpected toxicities were noted in these patients. All observed side effects had been previously described after various myeloablative conditioning programs [6] [7] [8] [9] . Evaluation from the late posttransplantation period (days 28 to 100) showed no new adverse events and recovery of all grade 3 toxicity, including previously noted liver toxicity. All 4 evaluable allogeneic transplantation patients developed grade I to II acute GVHD (1 patient, grade I; 
Outcomes
Patients were evaluated for engraftment and disease response to day 100. The 11 evaluable patients had engraftment at a median of 11 days (range, 10-20 days). Platelet levels were self-sustained at >20,000/µL at a median of 14 days (range, 11-23 days) ( Table 4 ). These results were comparable to our prior experience with the oral and IV BU/CY2 regimen of every-6-hour dosing schedules. Engraftment, based on peripheral blood counts (autologous patients) and bone marrow cytogenetic evaluation (allogeneic patients), was stable past day 100. Eight of 10 evaluable patients in this small cohort attained CR by day 100. The 2 patients with AML, who received autologous transplants, had clearance of circulating blasts but developed disease progression prior to day 100.
DISCUSSION
To date, studies of the IV BU formulation we used have demonstrated highly consistent and reproducible PK whether the dosing was every 6 hours [18] or, as in our study, every 12 hours [27] or 24 hours. There has been repeated demonstration of minimal intrapatient variability in the disposition of IV BU, as shown in the PK parameters, including AUC, CL, C max , and t 1/2 of this drug. The PK profile of the first dose can be a predictor of the later concentrations of the drug.
The total busulfan AUC in our study shows a slightly higher than expected cumulative AUC for group A. This effect may have been due to dosing on actual body weight rather than adjusting the dose for the obese patients. In group B, the 2 obese patients had a slight adjustment of the dose (0.85 of actual body weight), and the result was exposure closer to the expected level. If the AUC (Table 2) for patients in group A is multiplied by 8 and the AUC of group B is multiplied by 4 (number of doses per group), the range for the total AUC is 17,056 to 37,420 µM*min, the median being 24,682 µM*min. These results are in a range previously seen in studies with both oral [12, 13] and IV [18] dosing of busulfan. All the busulfan AUC values were above the accepted minimal level for efficacy of the drug previously mentioned by Slattery et al. [14] .
Excessive exposure to busulfan has been associated with higher morbidity and mortality [28] , which include central nervous system toxicity [29] . Despite the high systemic peak levels (C max ) of the drug, there was no new unexpected or unusual toxicity in our patients. Our study demonstrated levels above the reported "safety level" of the drug concentration. With an every-6-hour dosing schedule, patients with AUC values greater than 24,000 µM*min are more 
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prone to hepatic VOD [12, 13] . Six of the 12 patients (5 in group A, 1 in group B) in our study were above this threshold. Despite this finding, only 1 patient developed VOD in our study. This patient was well within the expected AUC range and may have had the process triggered by the administration of medroxyprogesterone. The lack of VOD in the patients with higher AUC levels may be explained several ways. First, the use of IV BU circumvents the first-pass hepatic effect. Because less of the drug passes through the liver initially, there is less depletion of the glutathione stores. Results of a recent retrospective analysis comparing oral to IV BU support this theory [30] . Second, the use of twice-daily and daily dosing may have allowed for glutathione-S-reductase and glutathione-S-transferase recovery between doses. Even if stores were depleted with each dose, the delay of the next dose would allow more recovery of the enzymes. In addition, at the end of the 24-hour dosing interval, there were minimally detectable busulfan levels in patients receiving the IV BU daily dosing. Finally, the time separation from the last dose of busulfan to the first dose of cyclophosphamide may contribute to reduce hepatic injury, as has been previously suggested [10, 14] .
There was no increase in tissue injury to the lungs, kidneys, heart, or liver as evidenced by results of serologic monitoring of surrogate end points (ie, creatinine, lactate dehydrogenase, and liver function tests). In our study there were no seizures or other central nervous system abnormalities. The higher concentrations had no effect on engraftment of the neutrophils or platelets. Median times to engraftment were similar to those seen historically at our center and to prior results with every-6-hour IV BU [18] .
The reproducible PK profile of IV BU is in stark contrast to the erratic and unpredictable PK values experienced with oral busulfan [12, 31, 32] . IV BU should allow for strategies with a test dose to predict a target AUC. The predictability of the drug also allows for a less frequent PK testing schedule and possibly the use of a more limited sampling set to be used for PK evaluation. The collection of 4 or 5 samples on the first dose has been validated in an every-6-hour schedule. It determines busulfan concentrations adequately to gather necessary PK information and allows for dose adjustments if needed [33] .
Our study provides evidence that twice-daily and daily dosing of IV BU appears to be safe with reproducible and favorable PK. Based on the PK profile, this strategy allows a consistent and accurate busulfan delivery at all dosing points. The results of this study suggest that twice-daily or daily dosing of IV BU and daily cyclophosphamide can be used as a pretransplantation conditioning regimen for patients with advanced hematologic malignant disease. Although we are encouraged by our preliminary results, we feel that further evaluation of both these dosing regimens, including PK studies and long-term efficacy, is warranted.
